Biomarkers of tuberculosis: A research roadmap

Biomarkers in Medicine

Volumn 7, Issue 3, 2013, Pages 349-362

  Whitworth, Hilary S ^a   Aranday Cortes, Elihu ^a   Lalvani, Ajit ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

biomarker; diagnosis; immune markers; latent TB infection; LTBI; metabolomics; prognosis; proteomics; TB; transcriptomics; treatment response; tuberculosis

Indexed keywords

ANTIGEN; BCG VACCINE; BIOLOGICAL MARKER; CXCL11 CHEMOKINE; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; PROTEIN RV3615C; PROTEIN RV3879C; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; BACTERIUM CULTURE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; GENE EXPRESSION PROFILING; HUMAN; IMMUNITY; INFECTION PREVENTION; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; METABOLOMICS; NONHUMAN; PROGNOSIS; PROTEOMICS; RELAPSE; REVIEW; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE; STERILIZING IMMUNITY; TRANSCRIPTOMICS; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; VACCINATION;

ANIMALS; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; HUMANS; TRANSLATIONAL MEDICAL RESEARCH; TUBERCULOSIS;

EID: 84878741295     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.53     Document Type: Review

References (122)

1. Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol. 178(5), 1274-1282 (1996).
2. Hampshire T, Soneji S, Bacon J et al. Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: a model for persistent organisms? Tuberculosis (Edinb.) 84(3-4), 228-238 (2004).
3. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nat. Rev. Immunol. 11(5), 343-354 (2011).
4. Ernst JD. The immunological life cycle of tuberculosis. Nat. Rev. Immunol. 12(8), 581-591 (2012).
5. Romano M, Huygen K. An update on vaccines for tuberculosis - there is more to it than just waning of BCG efficacy with time. Expert Opin. Biol. Ther. 12(12), 1601-1610 (2012).
6. Jacobs S, Warman A, Richardson R et al. The tuberculin skin test is unreliable in school children BCG-vaccinated in infancy and at low risk of tuberculosis infection. Pediatr. Infect. Dis. J. 30(9), 754-758 (2011).
7. Kim EY, Lim JE, Jung JY et al. Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect. Dis. 9, 207 (2009).
8. Pathan AA, Wilkinson KA, Klenerman P et al. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J. Immunol. 167(9), 5217-5225 (2001).
9. Lalvani A, Pathan AA, McShane H et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am. J. Respir. Crit. Care Med. 163(4), 824-828 (2001).
10. Lalvani A, Nagvenkar P, Udwadia Z et al. Enumeration of T cells specific for RD1- encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J. Infect. Dis. 183(3), 469-477 (2001).
11. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann. Int. Med. 149(3), 177-184 (2008).
12. Sester M, Sotgiu G, Lange C et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur. Respir. J. 37(1), 100-111 (2011).
13. Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 364(9452), 2196-2203 (2004).
14. Cattamanchi A, Smith R, Steingart KR et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J. Acquir. Immune Defic. Syndr. 56(3), 230-238 (2011).
15. Parida SK, Kaufmann SH. The quest for biomarkers in tuberculosis. Drug Discov. Today 15(3-4), 148-157 (2010).
16. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl. Tuberc. 26, 28-106 (1970).
17. Dosanjh DP, Hinks TS, Innes JA et al. Improved diagnostic evaluation of suspected tuberculosis. Ann. Int. Med. 148(5), 325-336 (2008).
18. Kumar N, Bhargava SK, Agrawal CS, George K, Karki P, Baral D. Chest radiographs and their reliability in the diagnosis of tuberculosis. JNMA J. Nepal Med. Assoc. 44(160), 138-142 (2005).
19. Schnippel K, Meyer-Rath G, Long L et al. Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop. Med. Int. Health 17(9), 1142-1151 (2012).
20. Wallis RS, Doherty TM, Onyebujoh P et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect. Dis. 9(3), 162-172 (2009).
21. Maertzdorf J, Weiner J 3rd, Kaufmann SH. Enabling biomarkers for tuberculosis control. Int. J. Tuberc. Lung Dis. 16(9), 1140-1148 (2012).
22. Kagina BM, Abel B, Bowmaker M et al. Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. Vaccine 27(40), 5488-5495 (2009).
23. Kagina BM, Abel B, Scriba TJ et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am. J. Respir. Crit. Care Med. 182(8), 1073-1079 (2010).
24. Soares AP, Kwong Chung CK, Choice T et al. Longitudinal changes in CD4+ T-cell memory responses induced by BCG vaccination of newborns. J. Infect. Dis. 207(7), 1084-1094 (2013).
25. Aranday Cortes E, Kaveh D, Nunez-Garcia J, Hogarth PJ, Vordermeier HM. Mycobacterium bovis-BCG vaccination induces specific pulmonary transcriptome biosignatures in mice. PLoS ONE 5(6), e11319 (2010).
26. Bhuju S, Aranday-Cortes E, Villarreal-Ramos B, Xing Z, Singh M, Vordermeier HM. Global gene transcriptome analysis in vaccinated cattle revealed a dominant role of IL-22 for protection against bovine tuberculosis. PLoS Pathog. 8(12), e1003077 (2012).
27. Mehra S, Alvarez X, Didier PJ et al. Granuloma correlates of protection against tuberculosis and mechanisms of immune modulation by Mycobacterium tuberculosis. J. Infect. Dis. 207(7), 1115-1127 (2013).
28. Fletcher HA, Keyser A, Bowmaker M et al. Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth. BMC Med. Genomics 2, 10 (2009).
29. Rowland R, McShane H. Tuberculosis vaccines in clinical trials. Expert Rev. Vaccines 10(5), 645-658 (2011).
30. Tameris MD, Hatherill M, Landry BS et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled Phase 2b trial. Lancet 381(9871), 1021-1028 (2013).
31. Von Reyn CF, Mtei L, Arbeit RD et al. Prevention of tuberculosis in Bacille Calmett-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 24(5), 675-685 (2010).
32. Gaucher D, Therrien R, Kettaf N et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205(13), 3119-3131 (2008).
33. Querec TD, Akondy RS, Lee EK et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10(1), 116-125 (2009).
34. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 9(10), 741-747 (2009).
35. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 174(7), 831-839 (2006).
36. Hussain R, Talat N, Shahid F, Dawood G. Longitudinal tracking of cytokines after acute exposure to tuberculosis: association of distinct cytokine patterns with protection and disease development. Clin. Vaccine Immunol. 14(12), 1578-1586 (2007).
37. Sridhar S, Pollock K, Lalvani A. Redefining latent tuberculosis. Future Microbiol. 6(9), 1021-1035 (2011).
38. Chapman AL, Munkanta M, Wilkinson KA et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 16(17), 2285-2293 (2002).
39. Nakaoka H, Lawson L, Squire SB et al. Risk for tuberculosis among children. Emerg. Infect. Dis. 12(9), 1383-1388 (2006).
40. Basu Roy R, Sotgiu G, Altet-Gomez N et al. Identifying predictors of interferon-gamma release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmett-Guerin?: a pTB-NET collaborative study. Am. J. Respir. Crit. Care Med. 186(4), 378-384 (2012).
41. Mutsvangwa J, Millington KA, Chaka K et al. Identifying recent Mycobacterium tuberculosis transmission in the setting of high HIV and TB burden. Thorax 65(4), 315-320 (2010).
42. Santin M, Munoz L, Rigau D. Interferon-gamma release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLoS ONE 7(3), e32482 (2012).
43. Santin M, Casas S, Saumoy M et al. Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-gamma release assay, and the development of active tuberculosis in HIV-seropositive persons. Diagn. Microbiol. Infect. Dis. 69(1), 59-65 (2011).
44. Leidl L, Mayanja-Kizza H, Sotgiu G et al. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. Eur. Respir. J. 35(3), 619-626 (2010).
45. Vincenti D, Carrara S, Butera O et al. Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study. Clin. Exp. Immunol. 150(1), 91-98 (2007).
46. Lalvani A, Millington KA. T-cell interferon-gamma release assays: can we do better? Eur. Respir. J. 32(6), 1428-1430 (2008).
47. Lalvani A, Millington KA. T cells and tuberculosis: beyond interferon-gamma. J. Infect. Dis. 197(7), 941-943 (2008).
48. Millington KA, Fortune SM, Low J et al. Rv3615c is a highly immunodominant RD1 (region of difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection. Proc. Natl Acad. Sci. USA 108(14), 5730-5735 (2011).
49. Ruhwald M, Petersen J, Kofoed K et al. Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10. PLoS ONE 3(8), e2858 (2008).
50. Ruhwald M, Dominguez J, Latorre I et al. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis (Edinb.) 91(3), 260-267 (2011).
51. Petrucci R, Abu Amer N, Gurgel RQ et al. Interferon gamma, interferon-gamma-induced-protein 10, and tuberculin responses of children at high risk of tuberculosis infection. Pediatr. Infect. Dis. J. 27(12), 1073-1077 (2008).
52. Alsleben N, Ruhwald M, Russmann H, Marx FM, Wahn U, Magdorf K. Interferon-gamma inducible protein 10 as a biomarker for active tuberculosis and latent tuberculosis infection in children: a case-control study. Scand. J. Infect. Dis. 44(4), 256-262 (2012).
53. Goletti D, Raja A, Syed Ahamed Kabeer B et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons? PLoS ONE 5(9), e12577 (2010).
54. Kasprowicz VO, Mitchell JE, Chetty S et al. A molecular assay for sensitive detection of pathogen-specific T-cells. PLoS ONE 6(8), e20606 (2011).
55. Bakir M, Millington KA, Soysal A et al. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann. Int. Med. 149(11), 777-787 (2008).
56. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 177(10), 1164-1170 (2008).
57. Rangaka MX, Wilkinson KA, Glynn JR et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis. 12(1), 45-55 (2012).
58. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 142(1), 63-75 (2012).
59. Dosanjh DP, Bakir M, Millington KA et al. Novel M tuberculosis antigen-specific T-cells are early markers of infection and disease progression. PLoS ONE 6(12), e28754 (2011).
60. Corbiere V, Pottier G, Bonkain F et al. Risk stratification of latent tuberculosis defined by combined interferon gamma release assays. PLoS ONE 7(8), e43285 (2012).
61. Sutherland JS, Hill PC, Adetifa IM et al. Identification of probable early-onset biomarkers for tuberculosis disease progression. PLoS ONE 6(9), e25230 (2011).
62. Hussain R, Talat N, Ansari A, Shahid F, Hasan Z, Dawood G. Endogenously activated interleukin-4 differentiates disease progressors and non-progressors in tuberculosis susceptible families: a 2-year biomarkers follow-up study. J. Clin. Immunol. 31(5), 913-923 (2011).
63. Ordway DJ, Costa L, Martins M et al. Increased interleukin-4 production by CD8 and gammadelta T cells in health-care workers is associated with the subsequent development of active tuberculosis. J. Infect. Dis. 190(4), 756-766 (2004).
64. Hinks TS, Dosanjh DP, Innes JA et al. Frequencies of region of difference 1 antigen-specific but not purified protein derivative-specific gamma interferon-secreting T cells correlate with the presence of tuberculosis disease but do not distinguish recent from remote latent infections. Infect. Immun. 77(12), 5486-5495 (2009).
65. Goletti D, Butera O, Vanini V et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur. Respir. J. 36(1), 135-142 (2010).
66. Whitworth HS, Scott M, Connell DW, Donges B, Lalvani A. IGRAs - the gateway to T cell based TB diagnosis. Methods doi:10.1016/j.ymeth.2012.12.012 (2013) (Epub ahead of print).
67. Berry MP, Graham CM, McNab FW et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466(7309), 973-977 (2010).
68. Chee CB, Khinmar KW, Gan SH, Barkham TM, Pushparani M, Wang YT. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am. J. Respir. Crit. Care Med. 175(3), 282-287 (2007).
69. Adetifa IM, Ota MO, Jeffries DJ et al. Interferon-gamma ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial. Am. J. Respir. Crit. Care Med. 187(4), 439-445 (2013).
70. Bartalesi F, Goletti D, Spinicci M et al. Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment. J. Infect. 66(4), 346-356 (2013).
71. Ling DI, Zwerling AA, Steingart KR, Pai M. Immune-based diagnostics for TB in children: what is the evidence? Paediatr. Respir. Rev. 12(1), 9-15 (2011).
72. Chiappini E, Della Bella C, Bonsignori F et al. Potential role of M. tuberculosis specific IFN-gamma and IL-2 ELISPOT assays in discriminating children with active or latent tuberculosis. PLoS ONE 7(9), e46041 (2012).
73. Casey R, Blumenkrantz D, Millington K et al. Enumeration of functional T-cell subsets by fluorescence-immunospot defines signatures of pathogen burden in tuberculosis. PLoS ONE 5(12), e15619 (2010).
74. Sester U, Fousse M, Dirks J et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. PLoS ONE 6(3), e17813 (2011).
75. Sargentini V, Mariotti S, Carrara S et al. Cytometric detection of antigen-specific IFN-gamma/IL-2 secreting cells in the diagnosis of tuberculosis. BMC Infect. Dis. 9, 99 (2009).
76. Harari A, Rozot V, Enders FB et al. Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat. Med. 17(3), 372-376 (2011).
77. Day CL, Abrahams DA, Lerumo L et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J. Immunol. 187(5), 2222-2232 (2011).
78. Petruccioli E, Petrone L, Vanini V et al. IFNgamma/TNFalpha specific-cells and effector memory phenotype associate with active tuberculosis. J. Infect. 66(6), 475-486 (2013).
79. Schuetz A, Haule A, Reither K et al. Monitoring CD27 expression to evaluate Mycobacterium tuberculosis activity in HIV-1 infected individuals in vivo. PLoS ONE 6(11), e27284 (2011).
80. Pollock KM, Whitworth HS, Montamat-Sicotte DJ et al. T-cell immunophenotyping distinguishes active from latent tuberculosis. J. Infect. Dis. (2013) (In press).
81. Rozot V, Vigano S, Mazza-Stalder J et al. Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease. Eur. J. Immunol. doi:10.1002/eji.201243262 (2013) (Epub ahead of print).
82. Wang S, Diao N, Lu C et al. Evaluation of the diagnostic potential of IP-10 and IL-2 as biomarkers for the diagnosis of active and latent tuberculosis in a BCG-vaccinated population. PLoS ONE 7(12), e51338 (2012).
83. Yu Y, Zhang Y, Hu S et al. Different patterns of cytokines and chemokines combined with IFN-gamma production reflect Mycobacterium tuberculosis infection and disease. PLoS ONE 7(9), e44944 (2012).
84. Sutherland JS, De Jong BC, Jeffries DJ, Adetifa IM, Ota MO. Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort. PLoS ONE 5(8), e12365 (2010).
85. Steingart KR, Flores LL, Dendukuri N et al. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. PLoS Med. 8(8), e1001062 (2011).
86. Raqib R, Rahman J, Kamaluddin AK et al. Rapid diagnosis of active tuberculosis by detecting antibodies from lymphocyte secretions. J. Infect. Dis. 188(3), 364-370 (2003).
87. Rekha RS, Kamal SM, Andersen P et al. Validation of the ALS assay in adult patients with culture confirmed pulmonary tuberculosis. PLoS ONE 6(1), e16425 (2011).
88. Raqib R, Mondal D, Karim MA et al. Detection of antibodies secreted from circulating Mycobacterium tuberculosis-specific plasma cells in the diagnosis of pediatric tuberculosis. Clin. Vaccine Immunol. 16(4), 521-527 (2009).
89. Thomas T, Brighenti S, Andersson J, Sack D, Raqib R. A new potential biomarker for childhood tuberculosis. Thorax 66(8), 727-729 (2011).
90. Ashenafi S, Aderaye G, Zewdie M et al. BCG-specific IgG-secreting peripheral plasmablasts as a potential biomarker of active tuberculosis in HIV negative and HIV positive patients. Thorax 68(3), 269-276 (2013).
91. Lalvani A, Connell DW. Tuberculosis immunodiagnosis: delving below the surface. Thorax 68(3), 204-206 (2013).
92. Maertzdorf J, Repsilber D, Parida SK et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun. 12(1), 15-22 (2011).
93. Ottenhoff TH, Dass RH, Yang N et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS ONE 7(9), e45839 (2012).
94. Jacobsen M, Repsilber D, Gutschmidt A et al. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J. Mol. Med. 85(6), 613-621 (2007).
95. Verhagen LM, Zomer A, Maes M et al. A predictive signature gene set for discriminating active from latent tuberculosis in Warao Amerindian children. BMC Genomics 14(1), 74 (2013).
96. Maertzdorf J, Ota M, Repsilber D et al. Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS ONE 6(10), e26938 (2011).
97. Sandhu G, Battaglia F, Ely BK et al. Discriminating active from latent tuberculosis in patients presenting to community clinics. PLoS ONE 7(5), e38080 (2012).
98. Liu Q, Chen X, Hu C et al. Serum protein profiling of smear-positive and smear-negative pulmonary tuberculosis using SELDI-TOF mass spectrometry. Lung 188(1), 15-23 (2010).
99. Liu JY, Jin L, Zhao MY et al. New serum biomarkers for detection of tuberculosis using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. Lab. Med. 49(10), 1727-1733 (2011).
100. Fu YR, Yi ZJ, Guan SZ, Zhang SY, Li M. Proteomic analysis of sputum in patients with active pulmonary tuberculosis. Clin. Microbiol. Infect. 18(12), 1241-1247 (2012).
101. Zhang J, Wu X, Shi L et al. Diagnostic serum proteomic analysis in patients with active tuberculosis. Clin. Chim. Acta 413(9-10), 883-887 (2012).
102. Deng C, Lin M, Hu C et al. Establishing a serologic decision tree model of extrapulmonary tuberculosis by MALDI-TOF MS analysis. Diagn. Microbiol. Infect. Dis. 71(2), 144-150 (2011).
103. Shin JH, Yang JY, Jeon BY et al. 1H NMR-based metabolomic profiling in mice infected with Mycobacterium tuberculosis. J. Proteome Res. 10(5), 2238-2247 (2011).
104. Somashekar BS, Amin AG, Rithner CD et al. Metabolic profiling of lung granuloma in Mycobacterium tuberculosis infected guinea pigs: ex vivo 1H magic angle spinning NMR studies. J. Proteome Res. 10(9), 4186-4195 (2011).
105. Somashekar BS, Amin AG, Tripathi P et al. Metabolomic signatures in guinea pigs infected with epidemic-associated W-Beijing strains of Mycobacterium tuberculosis. J. Proteome Res. 11(10), 4873-4884 (2012).
106. Weiner J 3rd, Parida SK, Maertzdorf J et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS ONE 7(7), e40221 (2012).
107. Bark CM, Thiel BA, Johnson JL. Pretreatment time to detection of Mycobacterium tuberculosis in liquid culture is associated with relapse after therapy. J. Clin. Microbiol. 50(2), 538 (2012).
108. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin. Infect. Dis. 38(5), 754-756 (2004).
109. Adetifa IM, Ota MO, Walther B et al. Decay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases. PLoS ONE 5(9), e12502 (2010).
110. Djoba Siawaya JF, Chegou NN, van den Heuvel MM et al. Differential cytokine/chemokines and KL-6 profiles in patients with different forms of tuberculosis. Cytokine 47(2), 132-136 (2009).
111. Mistry R, Cliff JM, Clayton CL et al. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J. Infect. Dis. 195(3), 357-365 (2007).
112. Joosten SA, Goeman JJ, Sutherland JS et al. Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay. Genes Immun. 13(1), 71-82 (2012).
113. Bloom CI, Graham CM, Berry MP et al. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS ONE 7(10), e46191 (2012).
114. Cliff JM, Lee JS, Constantinou N et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J. Infect. Dis. 207(1), 18-29 (2013).
115. Hesseling AC, Walzl G, Enarson DA et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int. J. Tuberc. Lung Dis. 14(5), 560-570 (2010).
116. Hamilton CD, Stout JE, Goodman PC et al. The value of end-of-treatment chest radiograph in predicting pulmonary tuberculosis relapse. Int. J. Tuberc. Lung Dis. 12(9), 1059-1064 (2008).
117. Chen YC, Chin CH, Liu SF et al. Prognostic values of serum IP-10 and IL-17 in patients with pulmonary tuberculosis. Dis. Markers 31(2), 101-110 (2011).
118. WHO. Global tuberculosis control: WHO report 2011. http://whqlibdoc.who. int/publications/2011/9789241564380-eng.pdf (Accessed 15 March 2013)
119. WHO. The global plan to stop TB: 2011-2006. www.stoptb.org/assets/ documents/global/plan/TB-GlobalPlanToStopTB2011-2015.pdf (Accessed 15 February 2013)
120. US CDC. BCG vaccine: fact sheet (2011). www.cdc.gov/tb/publications/ factsheets/prevention/bcg.htm (Accessed 15 March 2013)
121. Fine PE, Carneiro IA, Milstien JB, Clements CJ. Issues relating to the use of BCG in immunization programs: a discussion document. Department of Vaccines and Biologicals, WHO. www.who.int/vaccine-research/documents/en/bcg- vaccines.pdf (Accessed 15 March 2013)
122. WHO. Commercial serodiagnostic tests for diagnosis of tuberculosis: policy statement (2011). http://whqlibdoc.who.int/publications/2011/ 9789241502054-eng.pdf (Accessed 15 March 2013)